Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
3
4
15
4
5
11
Revenue Growth (YoY)
-77%
-73%
275%
-20%
-55%
-21%
Cost of Revenue
--
0
0
0
0
0
Gross Profit
--
3
15
4
5
11
Selling, General & Admin
28
30
30
24
33
43
Research & Development
95
88
71
61
57
81
Operating Expenses
125
119
91
100
104
145
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
-122
-114
-72
-95
-98
-159
Income Tax Expense
0
0
0
0
0
0
Net Income
-122
-114
-72
-96
-98
-159
Net Income Growth
39%
57.99%
-25%
-2%
-38%
-8%
Shares Outstanding (Diluted)
118.54
96.99
95.12
77.38
54.91
54.09
Shares Change (YoY)
23%
2%
23%
41%
2%
46%
EPS (Diluted)
-1.03
-1.17
-0.76
-1.24
-1.78
-2.95
EPS Growth
12%
54%
-38%
-31%
-40%
-37%
Free Cash Flow
-88
-105
-78
-52
-104
-163
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
75%
100%
100%
100%
100%
Operating Margin
-4,033.33%
-2,900%
-506.66%
-2,400%
-1,980%
-1,218.18%
Profit Margin
-4,066.66%
-2,850%
-480%
-2,400%
-1,960%
-1,445.45%
Free Cash Flow Margin
-2,933.33%
-2,625%
-520%
-1,300%
-2,080%
-1,481.81%
EBITDA
-119
-116
-76
-82
-89
-119
EBITDA Margin
-3,966.66%
-2,900%
-506.66%
-2,050%
-1,780%
-1,081.81%
D&A For EBITDA
2
0
0
14
10
15
EBIT
-121
-116
-76
-96
-99
-134
EBIT Margin
-4,033.33%
-2,900%
-506.66%
-2,400%
-1,980%
-1,218.18%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Key Stats
Prev.Close
$4.3
Open
$4.3
Day's Range
$4.3 - $4.3
52 week range
$0.0001 - $4.79
Volume
100
Avg.Volume
10
Dividend yield
--
EPS (TTM)
-1.12
Market Cap
$236.3M
What is DBV TECHNOLOGIES?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
